While the study found that semaglutide specifically reduced the risk of atrial arrhythmias and atrial fibrillation (AF), other studies have reported conflicting results regarding the arrhythmia risk associated with GLP-1 RAs (91). The gene discussed is GCG; the disease is atrial fibrillation.